Telomerase-specific replication-competent adenovirus, Telomelysin (OBP-301), has a human telomerase reverse transcriptase promoter that regulates viral replication and efficiently kills human cancer cells.
Introduction
Squamous cell carcinoma of the head and neck (SCCHN) accounts for 5% of newly diagnosed adult cancers in the United States and 8% of cancers worldwide (1) . Most patients are treated with various combinations of surgery, radiotherapy, and systemic agents (2) . Despite major advances in the treatment of locoregionally advanced SCCHN, such as the introduction of novel chemotherapy regimens and inhibitors of the epidermal growth factor receptor, treatment fails in about half of the patients (3). The median survival of patients with recurrent or metastatic SCCHN who undergo chemotherapy is 6 to 9 months (4). Therefore, a considerable number of patients with SCCHN need additional treatment as the disease progresses.
Virotherapy, the approach to treat cancer with virus, has been done in some clinical trials; for example, clinical trials primarily using p53 gene replacement (INGN-201; a replication-competent adenoviral-based vector expressing wild-type p53) have provided the basis for the design of ongoing randomized gene therapy clinical trials in SCCHN patients in the United States (5) . Although systemic administration is probably required in the case of micrometastatic disease, virotherapy has some promise when tumor is limited to the head and neck. SCCHN is a particularly attractive model because most primary and recurrent lesions are easily acceptable to direct injection (6) . Potential usage of virotherapy may include the perioperative application in the surgical wound and the addition of intratumoral (i.t.) virotherapy to current standard options, such as radiotherapy and/or chemotherapy.
Telomerase is a ribonucleoprotein complex responsible for the complete replication of chromosomal ends (7) . Many studies have shown the expression of telomerase activity in >85% of human cancers (8) but only in a few normal somatic cell types (9) . Telomerase activation is considered to be a critical step in carcinogenesis, and its activity is closely correlated with human telomerase reverse transcriptase (hTERT) expression (10) . Therefore, the hTERT proximal promoter can be used as a molecular switch for selective expression of target genes in tumor cells. Replication-selective tumor-specific adenoviruses are being developed as novel anticancer therapies (11 -14) . In this context, an adenoviral vector that drives E1A and E1B genes under the hTERT promoter has been developed, termed Telomelysin or OBP-301 (15) . OBP-301 can replicate in and lyse only cancer cells but not normal cells, and its strong cytotoxic activity were shown in a variety human cancer cells (15 -17) . Also, OBP-301-mediated oncolysis induces uric acid production as a danger signal and stimulates CTL activity via proteasome activator upregulation (18) .
The infection efficiency of recombinant adenoviral vectors varies widely depending on the expression of the primary receptor, the coxsackie adenovirus receptor (CAR); the secondary receptors, integrin a V h 3 and integrin a V h 5 ; and the tertiary receptor, heparan sulfate glycosaminoglycans (HSG; refs. 19, 20) . The first step is the attachment of the virus to the cell surface through CAR (20) . Following attachment, the internalization of the virus into cells occurs through the integrin receptors a V h 3 and a V h 5 that are expressed in most cell types (19) .
Previously, OBP-301 has been reported to induce cell death of human non-small cell lung, colorectal, and prostate cancers in vitro and in vivo (15, 17) . The present study investigates the cytotoxic activity of OBP-301 in 13 SCCHN cell lines and the association between cytotoxic activity and adenoviral receptor expression. We also assessed the in vivo antitumor activity and toxicity and tolerability of OBP-301 in an athymic nude mouse model with KCCT873 SCCHN tumors.
Materials and Methods

Adenovirus
The recombinant replication-selective, tumor-specific adenoviral vector OBP-301 was provided by Oncolys Biopharma. The hTERT promoter element drives the expression of E1A and E1B genes linked with an internal ribosome entry site (15). The virus particle (vp) titer-toinfection titer (plaque-forming units) ratios were 110:3.
Cells The human non-small cell lung cancer cell line H1299 was cultured in RPMI 1640 supplemented with 10% fetal bovine serum, 1 mmol/L HEPES (Nacalai Tesuque), 100 Ag/mL penicillin, and 100 Ag/mL streptomycin (Nacalai Tesuque). The SCCHN cell line HN12 was grown in MEM containing 10% fetal bovine serum, 100 Ag/mL penicillin, and 100 Ag/mL streptomycin. The SCCHN cell lines YCUT892, KCCT873, KCCT891, KCCL871, YCUM862, KCCOR891, YCUL891, YCUM911, YCUMS861, YCUT891, 012SCC, and Wmm-SCC (21) were cultured in RPMI 1640 containing 10% fetal bovine serum, 1 mmol/L HEPES, 100 Ag/mL penicillin, and 100 Ag/mL streptomycin.
Cell Viability Assay The XTT assay was done to measure cell viability. Briefly, cells were plated on 96-well plates at 1 Â Quantitative Real-time PCR Analysis Total RNA from cultured cells was obtained using the RNeasy Mini kit (Qiagen). Total RNA (f0.1 Ag) was used for reverse transcription. Reverse transcription was done at 22jC for 10 min and then at 42jC for 20 min. The hTERT mRNA copy number was determined by real-time quantitative reverse transcription-PCR using a LightCycler instrument and a LightCycler DNA TeloTAGGG kit (Roche Diagnostics). PCR amplification was run with activation at 95jC for 15 s, annealing at 58jC for 10 s, and extension at 72jC for 9 s.
Athymic Nude Mouse Models of Human Head and Neck Cancer
Five-to 6-week-old female athymic nude mice (BALB/c nu/nu) were obtained from SLC. Animal care was in Toxicity Assessment Blood samples and organs were collected from athymic nude mice at day 10 or 17 after i.t. administration of OBP-301 (3 Â 10 10 vp/d for days [5] [6] [7] [8] [9] . Organs from the experimental animals were fixed in 10% formalin, and 5 Am tissue sections were prepared and stained with H&E.
Statistical Analysis
Tumor volume on a given day was calculated by the following formula: (length of the tumor) Â (width of the tumor) 2 / 2. The statistical significance of tumor regression was calculated by the Student's t test.
Results
Cytotoxic Activity of OBP-301 to Various SCCHN Cell Lines
We first examined the effect of OBP-301 infection on the viability of SCCHN cell lines assessed by the XTT assay. Because OBP-301 showed slightly cytotoxic activity against 7 of 13 cell lines at a dose of 1,833 vp (50 plaque-forming units/cell), we assessed the ID 50 of OBP-301 using these 7 SCCHN cell lines ( Fig. 1; Table 1 ). As shown in Table 1 , OBP-301 shows modest to strong cytotoxic activity in the 7 cell lines tested, with the ID 50 varying from 759 to 9,204 vp. The cytotoxic activity of OBP-301 in these cell lines shows dose dependence (Fig. 1) . YCUT892 cells were most sensitive to OBP-301 followed by KCCT873, HN12, KCCT891, YCUM862, KCCL871, and KCCOR871 cells, suggesting that 2 of the SCCHN cell lines are most sensitive to OBP-301.
Expression of Adenovirus Receptors in SCCHN Cell Lines
Because the cytotoxic activity of OBP-301 was anticipated to be correlated with efficiency of adenoviral infection through CAR, integrin a V h 3 , integrin a V h 5 , or HSG receptors (22), we then assessed the expression levels of CAR on SCCHN cells using flow cytometry. As shown in Fig. 2A , all 7 SCCHN cell lines have been found to express detectable levels of CAR. However, as shown in Fig. 2B , correlation between the cytotoxic activity of OBP-301 and the expression level of CAR was not significant (correlation coefficient = À0.5). In addition, we assessed the expression of integrin a V h 3 , integrin a V h 5 , and HSG in SCCHN cell lines; however, the expression levels were not correlated with cytotoxic activity of OBP-301 (Fig. 2C) . We also assessed hTERT expression using the quantitative PCR method and found that all of the SCCHN cell lines express detectable levels of hTERT mRNA; however, there was no correlation between the expression levels and ID 50 of OBP-301 in these cells (data not shown). These results suggest that, although 7 of 13 SCCHN cell lines are sensitive to OBP-301, its ability to enter the cell is not necessarily correlated with the degree of cytotoxicity.
Antitumor Effect of OBP-301 in SCCHN-Bearing Animals
To assess the antitumor effect of OBP-301 in the animal model of human SCCHN, KCCT873 cells were implanted s.c. in athymic nude mice (6, 23) to examine the effect of OBP-301 at a variety of dosages in vivo. Mice received i.t. injections of OBP-301 at 3 Â 10 8 , 3 Â 10 9 , or 3 Â 10 10 vp for 3 days from days 5 to 7 after tumor implantation (Fig. 3) . Tumors grew to mean tumor volume of 32.2 F 4.5 mm 3 at day 5. As shown in Fig. 3, the 3 Â 10 8 dose of OBP-301 treatment was less effective against KCCT873 tumor growth. The mean tumor volume was 549 mm 3 on day 42, which is comparable with control tumor volume (910 mm 3 ). Higher doses of OBP-301 led to superior antitumor activity. The mean tumor volume of treated tumors was 130 mm 3 at 3 Â 10 9 vp and 67 mm 3 at 3 Â 10 10 vp, which is significantly smaller compared with the control tumor at day 42 (P < 0.0001). Remarkably, in addition to a 93% inhibition in tumor volume in mice receiving a 3 Â 10 10 vp dosage, 3 of 7 tumors completely disappeared by day 37, which persisted through day 42. These results suggest that OBP-301 shows a remarkable antitumor effect in a dosedependent manner in KCCT873 SCCHN tumors. Based on these findings, OBP-301 at a dosage of 3 Â 10 10 vp per injection shows the maximum tumor reduction effect.
Optimization of OBP-301 Injection Times in KCCT873 SCCHN Tumors
We next evaluated the treatment schedule of OBP-301 in s.c. xenografted KCCT873 tumor-bearing mice. Mice were treated i.t. with OBP-301 for 1, 3, or 5 subsequent days. The Toxicity Profile in MiceTreated with OBP-301 Finally, to assess the toxicity and safety profile of OBP-301 treatment, blood and major organs including heart, liver, lung, kidney, and spleen were collected from KCCT873 tumor-bearing athymic nude mice receiving i.t. OBP-301 (3 Â 10 10 vp/d for 5 days) on day 10 or 17 after tumor implantation. As shown in Table 2 , a blood serum chemistry analysis showed no remarkable changes in any variable in all the mice tested, except for a minor elevation of creatinine phosphokinase and aspartate aminotransferase in the OBP-301 treatment group. Similarly, no pathologic alterations were observed in any of the organs tested (data not shown). Although a slight necrosis was observed in livers from mice treated with i.t. OBP-301, all other organs from untreated control and OBP-301-treated mice did not show any evidence of toxicity. The result that all the treated mice tolerated therapy very well without any behavioral changes or toxicities in blood and pathology suggests that OBP-301 treatment leads to considerable antitumor activity without unwanted safety or toxicity issues.
Discussion
Although it has been reported that OBP-301 showed a strong anticancer activity in colorectal, prostate, and non-small cell lung cancer in vitro and in vivo, the effect of OBP-301 in SCCHN has not been pursued (17, 18, 24) . Therefore, in this study, we planned to assess the detailed antitumor and toxicity profile of OBP-301 in an animal model of SCCHN. OBP-301 induces cell death in 7 of 13 cell lines in vitro and shows dramatic antitumor effects in an animal model bearing KCCT873 tumors without significant toxicity.
OBP-301 showed cytotoxic activity in 7 of 13 SCCHN cell lines. Because the effect of OBP-301 against SCCHN cell lines was limited compared with that previously shown against human non-small cell lung, colorectal, and prostate cancer cell lines (14, 17) , we hypothesized that the limitation came from the lower viral infection rate. However, it is of interest to note that the expression levels of adenoviral receptors including CAR, integrins, and HSG are comparable between SCCHN and non-small cell lung cancer H1299 cell lines ( Fig. 2; data not shown) . In addition, we did not find a significant correlation between hTERT mRNA expression and the cytotoxic activity of OBP-301. These results suggest that various factors such as replication speed of viruses and the existence of unknown receptors might be involved in the cytotoxic activity of OBP-301.
The i.t. three-or five-time administration of OBP-301 dramatically inhibited the growth of KCCT873 tumors in vivo. The antitumor effect was actually superior to what we expected from our in vitro results. Previously, we reported that adenovirus present in blood of mice exists for at least 1 week after i.t. treatment with OBP-301 (15, 17) , and i.t. OBP-301 showed antitumor effects both in the injected primary tumor site and in tumors located at distant sites (17) . From these results, it is conceivable that OBP-301 attacked the xenografted KCCT873 tumor over and over through the bloodstream for at least 1 week after injection. It has been reported that oncolytic virus replication induces tumor-specific immune responses by stimulating uric acid production as a danger signal as well as accelerating tumor antigen cleaved by IFN-g-inducible PA28 expression (18) . Additionally, because it has been shown that telomerase is active in f80% to 90% of SCCHN tumor tissues as assessed by immunohistochemistry (25), we speculate that SCCHN cancer preferentially responds to OBP-301 treatment. These results may be the reason why the antitumor activity of OBP-301 is more profound in KCCT873 tumors than expected from our in vitro results. Therefore, the strong anticancer effect shown in these animal studies suggests that OBP-301 could be an attractive agent to accomplish an in situ radical cure of SCCHN patients. Although chemoradiotherapy, radiotherapy plus concurrent chemotherapy, has become the standard care for patients with unresectable SCCHN and organ preservation (26, 27) , it has recently been reported that cisplatin and fluorouracil with docetaxel plus chemoradiotherapy has a greater effect (28) . Because our previous study showed that OBP-401 containing a green fluorescent protein gene for monitoring viral replication (TelomeScan) showed enhanced antitumor efficacy in an in vivo human lung cancer model when given in combination with docetaxel, it is possible that combination of OBP-301 with conventional chemotherapy may be a powerful regimen for the treatment of SCCHN in the clinic (29) . Additionally, as SCCHN is easily acceptable site for direct injection (6) and i.t. OBP-301 was emerged strong antitumor effect in the xenografted KCCT873 tumor, the i.t. OBP-301 may be a new tool for the treatment of head and neck cancer. Future directions of clinical exploration with OBP-301 are still being considered. Utilization of OBP-301 via i.t. injection appears to be associated with modest activity, although clinical utility of local regional therapy is limited. Further exploration via intrahepatic arterial infusion or i.v. infusion awaits discovery of methods to improve OBP-301 activity.
Viral replication generally results in tissue destruction. In fact, interactions between adenovirus type 5 with CAR, integrin a V h 3 , integrin a V h 5 , or HSG and the fiber shaft of adenovirus type 5 are known to be involved in accumulation in the liver of mice and cynomolgus monkeys when administered (30 -33) . In this study, a significant therapeutic effect of i.t. OBP-301 treatment was achieved without any significant liver toxicity. Histologic analyses in the brain, lung, heart, kidney, and spleen showed no toxicity profile. Oncolytic viruses have been developed as anticancer agents because controlled replication in the tumors causes selective killing of tumor cells and minimizes the effect on normal cells (34) . Thus, the current results are consistent with the mechanism of action of virotherapy with oncolytic viruses.
Notably, a phase I study of OBP-301 has been initiated in the United States to test the safety and tolerability of OBP-301 in patients with various types of progressive solid cancer including SCCHN. Results from current clinical trials may further show additional information on its safety and efficacy. As for the clinical use of OBP-301 in SCCHN, the preliminary information obtained from our study is, based on the present results, considered to be useful for the planning of future clinical trials.
In conclusion, this study clearly shows that OBP-301 has remarkable in vivo anticancer effects against SCCHN. These findings suggest that the replication-selective oncolytic virus provides a new platform for treating patients with human head and neck cancer.
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